Alnylam Pharmaceuticals (ALNY) to Release Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is set to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.75) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.68) EPS. On average, analysts expect Alnylam Pharmaceuticals to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alnylam Pharmaceuticals Trading Down 1.6 %

Shares of ALNY stock opened at $143.80 on Thursday. Alnylam Pharmaceuticals has a twelve month low of $143.50 and a twelve month high of $218.88. The stock has a market cap of $18.11 billion, a P/E ratio of -40.39 and a beta of 0.39. The stock has a 50 day moving average of $150.77 and a 200 day moving average of $166.28.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ALNY. Wells Fargo & Company decreased their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a research note on Friday, February 16th. Wolfe Research began coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, February 1st. Nine analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $216.12.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.